Hey! Just because you look at penny stocks and see that they are $5 or less per share, don’t think you should just ignore them. As we’ve seen, even recently, penny stocks have been able to make triple-digit returns in the short-term like no others. Remember, risk and reward are both significant. Today, I want you to check out these 3 stocks that all have significant press releases that could have them popping up on radars everywhere.

Here’s Your Top #1 Penny Stock To Watch Closely Today: Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company’s lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

La Jolla Pharmaceutical Company which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, and Tetraphase Pharmaceuticals, Inc. announced that they have entered into a definitive merger agreement. Under the terms of the definitive merger agreement, La Jolla would acquire Tetraphase, through a tender offer, for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights (CVRs). The Board of Directors of Tetraphase unanimously recommends that stockholders tender their shares in the La Jolla tender offer once it is commenced.

Under the terms of the definitive merger agreement, the upfront cash consideration in the transaction will be as follows: (i) $2.00 per share of Tetraphase common stock (including common stock underlying restricted stock units, performance-based stock units and pre-funded warrants); (ii) $2.68 per share of Tetraphase common stock underlying the common stock warrants issued by Tetraphase in November 2019; and (iii) $2.69 per share of Tetraphase common stock underlying the common stock warrants issued by Tetraphase in January 2020. Tetraphase equity holders would also be entitled to receive, for each share of Tetraphase common stock, one non-tradeable CVR. The holders of the CVRs would be entitled to receive payments of up to an additional $16.0 million in the aggregate upon the achievement of certain net sales of XERAVA™ in the United States (U.S.) as follows: (i) $2.5 million if 2021 XERAVA U.S. net sales are ≥ $20 million; (ii) $4.5 million if XERAVA U.S. net sales are ≥ $35 million during any calendar year ending on or prior to December 31, 2024; and (iii) $9.0 million if XERAVA U.S. net sales are ≥ $55 million during any calendar year ending on or prior to December 31, 2024.

“Combining with La Jolla, which markets GIAPREZA, the first new treatment for patients suffering from septic or other distributive shock in more than a decade, should help accelerate XERAVA’s availability to patients in need,” said Larry Edwards, President and Chief Executive Officer of Tetraphase. “We are excited to have the opportunity to combine with a company that has a strategic vision similar to our own.”

“We commend Tetraphase on its successful commercial launch of XERAVA, an important new treatment for patients suffering from serious infections,” said Kevin Tang, Chairman of La Jolla. “By increasing our presence in the hospital with a second innovative therapy, we look forward to better serving the needs of patients suffering from life-threatening diseases.”

Here’s Your Top #2 Penny Stock To Watch Closely Today: Professional Diversity Network, Inc.

Professional Diversity Network, Inc. (Nasdaq: IPDN) operates online professional networking communities with career resources in the United States. It operates in two segments, Professional Diversity Network (PDN Network) and National Association of Professional Women (NAPW Network). The PDN Network segment offers single and multiple job postings, recruitment media, talent recruitment communities, corporate memberships, hiring campaign marketing and advertising, e-newsletter marketing, and research and outreach services to various cultural groups and employers. It also provides consumer advertising and consumer marketing solutions through advertising and job postings on its Websites.

The Nasdaq Stock Market® (NDAQ) announced that trading in Professional Diversity Network, Inc. (IPDN) is scheduled to resume on Wednesday, June 24, 2020, at 7:00 a.m. Eastern Time. Trading in the company’s stock was halted on November 26, 2019 at 4:51:27 p.m. Eastern Time.

For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site.

Here’s Your Top #3 Penny Stock To Watch Closely Today: Biocept, Inc.

Biocept, Inc. (Nasdaq: BIOC), an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company’s cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. The company’s Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from ctDNA.

Biocept, Inc. announced it has entered into a managed care provider agreement with Medical Cost Containment Professionals, LLC (MCCP) to process out-of-network claims for Biocept’s Target Selector™ liquid biopsy testing.  MCCP is a reference-based pricing insurance network that includes more than 150,000 providers nationwide.

“MCCP has a reputation for paying out-of-network claims correctly, in full and on time; and we are delighted to be working with them,” said Dede Goehler, Biocept’s Senior Director of Managed Care Strategies. “Under this new relationship, out-of-network claims for our Target Selector™ testing will be adjudicated by MCCP at pre-negotiated pricing in a timely manner, helping to accelerate collections while reducing the length of time receivables remain outstanding.”

“This agreement effectively expands our managed care network of covered lives at a time when the healthcare community increasingly recognizes the importance of our liquid biopsy tests in helping physicians to determine the optimal treatment for their patients with cancer,” said Michael Nall, Biocept’s President and CEO. “MCCP’s network includes 47 million covered lives, with some members covered by multiple plans.  We are working to enter into additional similar partnerships that help adjudicate out-of-network claims, as well as with managed care plans for in-network coverage for their members.”